Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Dyne Therapeutics, Inc.

Dyne Therapeutics to Present at November Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics to Present at October Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics to Present at Jefferies Healthcare Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics’ Preclinical Data Demonstrating FORCE™ Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE™ Platform Delivery to CNS
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics to Present at Upcoming Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics to Present at Investor Conferences in November
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 at World Muscle Society 2022 Congress
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.